Drug Patent List
Oppositions
Newsletter
Weekly Digest

Pharsight

Advil Allergy Sinus Patent Expiration

Advil Allergy Sinus is a drug owned by Haleon Us Holdings Llc. It is protected by 1 US drug patent filed in 2013 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Feb 28, 2027. Details of Advil Allergy Sinus's patents and their expiration are given in the table below.


Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7863287 Compositions of non-steroidal anti-inflammatory drugs, decongestants and anti-histamines
Feb, 2027

(2 years from now)

Active


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Advil Allergy Sinus's patents.

Given below is the list of recent legal activities going on the following patents of Advil Allergy Sinus.

Event Date Patent/Publication
Patent litigations
Payment of Maintenance Fee, 12th Year, Large Entity 22 Jun, 2022 US7863287
Correspondence Address Change 05 Nov, 2019 US7863287
Payment of Maintenance Fee, 8th Year, Large Entity 12 Jun, 2018 US7863287
Recordation of Patent Grant Mailed 04 Jan, 2011 US7863287
Patent Issue Date Used in PTA Calculation 04 Jan, 2011 US7863287
Email Notification 16 Dec, 2010 US7863287
Issue Notification Mailed 15 Dec, 2010 US7863287
Application Is Considered Ready for Issue 08 Dec, 2010 US7863287
Dispatch to FDC 08 Dec, 2010 US7863287
Issue Fee Payment Received 06 Dec, 2010 US7863287

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Several oppositions have been filed on Advil Allergy Sinus's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Advil Allergy Sinus's generic, the next section provides detailed information on ongoing and past EP oppositions related to Advil Allergy Sinus patents.

Advil Allergy Sinus's oppositions filed in EPO

Advil Allergy Sinus has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Jan 23, 2015, by Galenicum Health S.L.. This opposition was filed on patent number EP03813818A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP03813818A Jan, 2015 Galenicum Health S.L. Revoked


US patents provide insights into the exclusivity only within the United States, but Advil Allergy Sinus is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Advil Allergy Sinus's family patents as well as insights into ongoing legal events on those patents.

Advil Allergy Sinus's family patents

Advil Allergy Sinus has patent protection in a total of 18 countries. It's US patent count contributes only to 14.7% of its total global patent coverage. 4 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree for Advil Allergy Sinus.

Family Patents

Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳



Generic Launch

Generic Release Date:

Advil Allergy Sinus's generic launch date based on the expiry of its last outstanding patent is estimated to be Feb 28, 2027 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Advil Allergy Sinus Generics:

There are no approved generic versions for Advil Allergy Sinus as of now.





About Advil Allergy Sinus

Advil Allergy Sinus is a drug owned by Haleon Us Holdings Llc. Advil Allergy Sinus uses Chlorpheniramine Maleate; Ibuprofen; Pseudoephedrine Hydrochloride as an active ingredient. Advil Allergy Sinus was launched by Haleon Us Holdings in 2002.

Market Authorisation Date:

Advil Allergy Sinus was approved by FDA for market use on 19 December, 2002.

Active Ingredient:

Advil Allergy Sinus uses Chlorpheniramine Maleate; Ibuprofen; Pseudoephedrine Hydrochloride as the active ingredient. Check out other Drugs and Companies using Chlorpheniramine Maleate; Ibuprofen; Pseudoephedrine Hydrochloride ingredient

Dosage:

Advil Allergy Sinus is available in tablet form for oral use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
2MG;200MG;30MG TABLET Over the counter ORAL